KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Cash from Operations (2016 - 2025)

Acadia Pharmaceuticals has reported Cash from Operations over the past 16 years, most recently at 48731000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 48731000.0 for Q4 2025, down 220.68% from a year ago — trailing twelve months through Dec 2025 was 109836000.0 (down 30.36% YoY), and the annual figure for FY2025 was 109836000.0, down 30.36%.
  • Cash from Operations for Q4 2025 was 48731000.0 at Acadia Pharmaceuticals, down from 74288000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for ACAD hit a ceiling of 85389000.0 in Q4 2023 and a floor of 76329000.0 in Q1 2022.
  • Median Cash from Operations over the past 5 years was 6926000.0 (2022), compared with a mean of 2228100.0.
  • Peak annual rise in Cash from Operations hit 457.97% in 2023, while the deepest fall reached 8009.35% in 2023.
  • Acadia Pharmaceuticals' Cash from Operations stood at 23120000.0 in 2021, then dropped by 3.17% to 23854000.0 in 2022, then skyrocketed by 457.97% to 85389000.0 in 2023, then crashed by 52.71% to 40381000.0 in 2024, then tumbled by 220.68% to 48731000.0 in 2025.
  • The last three reported values for Cash from Operations were 48731000.0 (Q4 2025), 74288000.0 (Q3 2025), and 63956000.0 (Q2 2025) per Business Quant data.